LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Accueil・Liste d'Actions・Beam Therapeutics Inc

Beam Therapeutics Inc

Fermé

SecteurSoins de santé

27.92 -5.07

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

27.71

Max

28.04

Chiffres clés
By Trading Economics
Revenu	-339M -94M
Ventes	-82M 32M
BPA	-0.91
Marge bénéficiaire	-297.177
Employés	522
EBITDA	-362M -102M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+78.7% upside

Dividendes
By Dow Jones
Prochains Résultats	4 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	176M 3.3B
Ouverture précédente	32.99
Clôture précédente	27.92

Sentiment de l'Actualité

By Acuity

19%

81%

33 / 345 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

16.225 / 20.17 Support & Résistance

Beam Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

15 mai 2026, 22:47 UTC

Actions en Tendance

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15 mai 2026, 22:16 UTC

Acquisitions, Fusions, Rachats

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15 mai 2026, 22:00 UTC

Principaux Mouvements du Marché

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15 mai 2026, 18:09 UTC

Principaux Mouvements du Marché

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

15 mai 2026, 16:02 UTC

Résultats

Principaux Mouvements du Marché

Forward Industries Shares Fall on New Debt as Solana Value Drops

15 mai 2026, 14:55 UTC

Principaux Mouvements du Marché

Aardvark Therapeutics Shares Plunge After FDA Hold on ARD-101 New Drug Application

15 mai 2026, 14:43 UTC

Principaux Mouvements du Marché

Chip Stocks Slide After U.S.-China Summit Ends Without Major Tech Deals -- Update

15 mai 2026, 22:17 UTC

Acquisitions, Fusions, Rachats

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mai 2026, 21:59 UTC

Acquisitions, Fusions, Rachats

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15 mai 2026, 21:50 UTC

Acquisitions, Fusions, Rachats

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mai 2026, 21:30 UTC

Acquisitions, Fusions, Rachats

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15 mai 2026, 21:16 UTC

Market Talk

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15 mai 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 mai 2026, 20:19 UTC

Actions en Tendance

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15 mai 2026, 19:41 UTC

Acquisitions, Fusions, Rachats

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15 mai 2026, 19:35 UTC

Market Talk

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15 mai 2026, 19:33 UTC

Market Talk

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15 mai 2026, 18:35 UTC

Résultats

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

15 mai 2026, 17:28 UTC

Market Talk

U.S. Oil Rig Count Rises by 5 to 415 -- Market Talk

15 mai 2026, 16:50 UTC

Acquisitions, Fusions, Rachats

Microsoft Stock Moves Higher After Ackman Announces New Stake -- WSJ

15 mai 2026, 16:24 UTC

Acquisitions, Fusions, Rachats

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 3rd Update

15 mai 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

15 mai 2026, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 mai 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 mai 2026, 15:55 UTC

Market Talk

Canada's 1Q Rebound Not a Turning Point -- Market Talk

15 mai 2026, 15:20 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 mai 2026, 15:20 UTC

Market Talk

Silver Plunges on Inflation Worries -- Market Talk

15 mai 2026, 15:20 UTC

Résultats

A Micron and Sandisk Peer Is Coming to U.S. Markets. What to Know About Japan's Kioxia. -- Barrons.com

15 mai 2026, 14:33 UTC

Market Talk

Dollar Could Drift Higher as it Retains High-Yielding Status -- Market Talk

Comparaison

Variation de prix

Beam Therapeutics Inc prévision

Objectif de Prix

By TipRanks

78.7% hausse

Prévisions sur 12 Mois

Moyen 49.91 USD 78.7%

Haut 80 USD

Bas 26 USD

Basé sur 12 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

12 ratings

Achat

Maintien

Vente

Basé sur 12 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

16.225 / 20.17Support & Résistance

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

33 / 345Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.